Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its fourth quarter and full year 2021 financial results, alongside financial guidance for 2022, on February 9, 2022, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Investors can join the call by dialing specific numbers for the U.S., Israel, and international participants. A replay will also be available. Teva, a leader in generic and specialty medicines, has a portfolio of over 3,500 products, impacting 200 million patients globally.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that its President & CEO, Kåre Schultz, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, starting at 9:45 A.M. Eastern Time. Investors can access a live webcast of the event via Teva's Investor Relations website. An archived version will be available within 24 hours and accessible for 30 days. With over 3,500 products, Teva is a global leader in generic and specialty medicines, improving lives for over a century.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announces plans to appeal a recent unfavorable legal ruling regarding opioid prescriptions. The company argues that the plaintiffs failed to provide evidence of wrongdoing, including medically unnecessary prescriptions or harm caused by Teva's actions. Teva emphasizes its commitment to increasing access to essential medicines and is pursuing a national settlement. Recent court rulings in California and Oklahoma have found no evidence of public nuisance related to Teva's opioid marketing practices.
Teva Pharmaceutical Industries has launched a first-to-market generic version of Narcan® (naloxone hydrochloride nasal spray) in the United States. This prescription medicine addresses opioid emergencies like overdoses, allowing for immediate intervention. Teva boasts the largest portfolio of FDA-approved generic products, with nearly 550 available, and holds a leading position in first-to-file opportunities, with around 100 pending in the U.S. Currently, 1 in 12 generic prescriptions in the U.S. is for a Teva generic, enhancing its market presence.
Teva Pharmaceuticals has launched an authorized generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide) in the United States, enhancing its portfolio of generic medicines. This topical treatment for acne vulgaris is notable as it is the first authorized generic for this product in the U.S. Epiduo® Forte Gel generated annual sales of $253 million in the U.S. as of September 2021. Teva holds the largest portfolio of FDA-approved generic products with nearly 550 medications available and around 100 pending first-to-files in the U.S.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced an increase in its tender offers' total maximum amount from $3.5 billion to $4 billion for various senior notes. The company raised the tender caps for the Pool 1 Notes to $2.996 billion and the Pool 2 Notes to $1.013 billion. Teva plans to finance these offers using proceeds from a debt securities offering that closed on November 9, 2021. The Offers are set to expire on November 24, 2021, with settlement expected on November 12, 2021.
Teva Pharmaceuticals presented interim results from the FINESSE study at the German Society of Neurology (DGN) Congress 2021. The study evaluates the effectiveness of fremanezumab in chronic and episodic migraine patients. Data from 574 patients indicated a 48.7% achievement of the primary endpoint—a ≥ 50% reduction in migraine days after 6 months. Additionally, significant reductions in migraine days, disability scores, and acute medication use were observed. Overall, these findings align with previous Phase III studies and highlight fremanezumab's effectiveness in real-life settings.
Summary not available.
Summary not available.
Teva Pharmaceutical Industries Limited has achieved a legal victory as Judge Peter Wilson of the Superior Court in California ruled that Teva did not cause a public nuisance regarding opioid marketing in Orange County, Los Angeles County, Santa Clara County, and Oakland. The court also found that Teva did not engage in false or misleading advertising practices. Teva emphasizes the need for comprehensive settlements to support those affected by opioid addiction, while it remains committed to providing affordable medicines globally.